Pregled bibliografske jedinice broj: 1260349
Pretreatment Ki-67 and the efficacy of neoadjuvant chemotherapy in breast cancer
Pretreatment Ki-67 and the efficacy of neoadjuvant chemotherapy in breast cancer // Lib Oncol. 2020 ; 48(Suppl 1)
Zagreb, 2020. str. 107-107 (poster, domaća recenzija, sažetak, stručni)
CROSBI ID: 1260349 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pretreatment Ki-67 and the efficacy of neoadjuvant
chemotherapy in breast cancer
Autori
Ramić, Snježana ; Perić Balja, Melita ; Smajlbegović, Velda ; Marušić, Marija ; Orešic, Tomislav ; Milas, Ivan
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Lib Oncol. 2020 ; 48(Suppl 1)
/ - Zagreb, 2020, 107-107
Skup
13. Hrvatski onkološki kongres
Mjesto i datum
Opatija, Hrvatska, 03.09.2020. - 06.09.2020
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
Breast cancer, neoadjuvant chemotherapy, Ki67 proliferation marker
Sažetak
Nowadays neoadjuvant chemotherapy (NAC) is the standard treatment for advanced breast cancer(BC) decreasing the extent of surgery.Many studies showed that the Ki67 proliferation marker could predict response to NAC. According to our results, high expression of Ki67 in biopsy and a decrease in surgical specimens suggests a sensibility to neoadjuvant chemotherapy.Our results suggest that tumors with Ki67 over 40% have better response to NAC, but we cannot state that Ki67 is a predictor of NAC, especially not for all intrinsic subtypes equally.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za tumore
Profili:
Snježana Ramić
(autor)
Marija Marušić
(autor)
Melita Perić Balja
(autor)
Ivan Milas
(autor)
